Pathogens do not operate in silos.
The same biological vulnerabilities appear across human health, agriculture, wildlife, and environmental systems.

Our work is grounded in a simple scientific truth: shared pathogen biology can be addressed through a unified antimicrobial platform.

Derived from Prunus maackii bark, our patented, multi-compound extract demonstrates broad-spectrum antimicrobial activity, including inhibition of filamentous fungi, Candida species, and oomycetes.

Rather than developing isolated products for isolated markets, we are building a scalable platform designed to translate across approximately 32 addressable verticals.

This is not incremental innovation.
It is a cross-domain biological strategy.